Symbols

CSBR

Champions Oncology·NASDAQ

--(--)

CSBR fundamentals

CSBR Q3 2026 Earnings

Champions Oncology (CSBR) released its earnings on Mar 12, 2026: revenue was 16.56M (YoY -2.82%), missed estimates; EPS was -0.02 (YoY -105.56%), missed estimates.

Revenue / YoY

16.56M

-2.82%

EPS / YoY

-0.02

-105.56%

Report date

Mar 12, 2026

CSBR Earnings Call Summary for Q3,2026

Revenue Resilience: Core services revenue up 32% YoY, offsetting data revenue decline, with Q3 EBITDA positive for the third straight quarter.
Data Business Breakthrough: First 6-figure data deal for Q4 and incremental revenue from prior large deal, signaling commercial viability.
Cost Efficiency: Outsourced lab costs ($2 million)拖累 gross margin至47%, but in-house transition could improve margins to >50%.
Corellia Funding: Active discussions for external financing, with potential redeployment of EBITDA into data initiatives or bottom-line growth.

Earnings

EPS

Revenue

Revenue & Expenses

CSBR has released its 2026 Q3 earnings report, with revenue of 16.56M, reflecting a YoY change of -2.82%, and net profit of -279.00K, showing a YoY change of -106.21%. The Sankey diagram below clearly presents CSBR's revenue sources and cost distribution.

Key Indicators

Champions Oncology (CSBR) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Champions Oncology (CSBR)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Champions Oncology (CSBR)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Champions Oncology (CSBR)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown